Herclon 440 MG Injection

Herclon 440mg Injection contains Trastuzumab as its active ingredient, which is indicated for the treatment of HER2-positive breast cancer. In patients with HER2 positivity, the breast cancer cells predominantly feature HER2 proteins that facilitate the rapid growth of cancer tumors by acting as signals to the malignant cells. This medication is also utilized for treating metastatic gastric cancer characterized by elevated levels of HER2 proteins.

HER2-positive breast cancers are known for their aggressive nature. The targeted therapy for HER2-positive breast cancer functions by specifically targeting the proteins that contribute to the growth, development, and dissemination of cancer. It is essential to use effective birth control during the treatment and for at least seven months following the last dose.

Herclon 440mg Injection is not advised for individuals under 18 years of age or for those with severe respiratory issues or who require oxygen therapy. It is crucial to inform your physician if you have any heart conditions, experience breathlessness, or have previously undergone any other cancer treatments. Ensure that you disclose all medications, including supplements and herbal products, you are currently taking before commencing treatment with this medication.